Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-4321 in Healthy Volunteers
NCT06877611Phase 1Recruiting
- Sponsor
- Seismic Therapeutic
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of S-4321 in rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Seismic Therapeutic. Primary endpoint: Number of participants with treatment-related adverse and serious adverse events at 2 months. Started Apr 2025; status: recruiting.
02
Drugs
S-4321
03
Conditions
rheumatoid arthritis (RA)inflammatory bowel disease (IBD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06877611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877611.